BerGenBio

BerGenBio:
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to identify patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO).
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO).
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
COVID-19, Fibrosis, Infectious Disease, Oncology
Finance
Pre-Revenues
Investement Strategy
Under the Radar
Listing
Europe, Public
Market Cap
100MM - 500MM
Website:
Profiles:
Address:
Jonas Lies vei 91
Bergen, Hordaland 5009
Norway
Bergen, Hordaland 5009
Norway
Presentation:
More info:
My account:
Company Participants at Solebury Trout Virtual Management Access Event - 1x1 conference calls
- Richard Godfrey, CEO
Lead Programs
Bemcentinib
Indication | Phase |
---|---|
NSCLC | 2 |
NSCLC | 2 |
NSCLC | 2 |
TNBC | 2 |
Melanoma | 2 |
AML | 2 |
BGB149
Indication | Phase |
---|---|
Cancer | 1 |
Top 10 Holders of BerGenBio ASA
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Nordea Investment Management AB (Norway) | 8.18 | 4,997,462 | 20.53 | Stakes | 11/4/20 |
Alfred Berg Kapitalforvaltning AS | 6.21 | 3,793,133 | 15.58 | Stakes | 11/4/20 |
Fjärde AP-fonden | 4.31 | 2,633,298 | 10.82 | Stakes | 11/4/20 |
MP Pensjon PK | 2.58 | 1,572,983 | 6.46 | Stakes | 11/4/20 |
KLP Kapitalforvaltning AS | 2.52 | 1,540,000 | 6.33 | Stakes | 11/4/20 |
Rhenman & Partners Asset Management AB | 1.26 | 1,097,993 | 4.51 | Funds | 6/30/20 |
First Fondene AS | 0.60 | 520,039 | 2.14 | Funds | 6/30/20 |
DNB Asset Management AS | 0.65 | 398,828 | 1.64 | Funds | 10/30/20 |
Storebrand Asset Management AS | 0.52 | 319,383 | 1.31 | Funds | 11/30/20 |
RAM Active Investments SA | 0.26 | 229,588 | 0.94 | Funds | 6/30/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.